Cargando…
Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of AT...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445304/ https://www.ncbi.nlm.nih.gov/pubmed/25990108 http://dx.doi.org/10.1186/s12967-015-0517-x |
_version_ | 1782373268714422272 |
---|---|
author | Zscharnack, Matthias Krause, Christoph Aust, Gabriela Thümmler, Christian Peinemann, Frank Keller, Thomas Smink, Jeske J. Holland, Heidrun Somerson, Jeremy S. Knauer, Jens Schulz, Ronny M. Lehmann, Jörg |
author_facet | Zscharnack, Matthias Krause, Christoph Aust, Gabriela Thümmler, Christian Peinemann, Frank Keller, Thomas Smink, Jeske J. Holland, Heidrun Somerson, Jeremy S. Knauer, Jens Schulz, Ronny M. Lehmann, Jörg |
author_sort | Zscharnack, Matthias |
collection | PubMed |
description | BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. METHODS: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). RESULTS: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. CONCLUSIONS: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0517-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4445304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44453042015-05-28 Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) Zscharnack, Matthias Krause, Christoph Aust, Gabriela Thümmler, Christian Peinemann, Frank Keller, Thomas Smink, Jeske J. Holland, Heidrun Somerson, Jeremy S. Knauer, Jens Schulz, Ronny M. Lehmann, Jörg J Transl Med Research BACKGROUND: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. METHODS: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). RESULTS: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. CONCLUSIONS: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0517-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-05-20 /pmc/articles/PMC4445304/ /pubmed/25990108 http://dx.doi.org/10.1186/s12967-015-0517-x Text en © Zscharnack et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Zscharnack, Matthias Krause, Christoph Aust, Gabriela Thümmler, Christian Peinemann, Frank Keller, Thomas Smink, Jeske J. Holland, Heidrun Somerson, Jeremy S. Knauer, Jens Schulz, Ronny M. Lehmann, Jörg Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title | Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title_full | Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title_fullStr | Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title_full_unstemmed | Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title_short | Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP) |
title_sort | preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (atmp) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445304/ https://www.ncbi.nlm.nih.gov/pubmed/25990108 http://dx.doi.org/10.1186/s12967-015-0517-x |
work_keys_str_mv | AT zscharnackmatthias preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT krausechristoph preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT austgabriela preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT thummlerchristian preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT peinemannfrank preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT kellerthomas preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT sminkjeskej preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT hollandheidrun preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT somersonjeremys preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT knauerjens preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT schulzronnym preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp AT lehmannjorg preclinicalgoodlaboratorypracticecompliantsafetystudytoevaluatebiodistributionandtumorigenicityofacartilageadvancedtherapymedicinalproductatmp |